Not sure how to use your Gate Post Growth Points? We've got you covered!
Growth Points Lucky Draw Round 1️⃣ 1️⃣ is coming soon!
Post, comment, like, and join chats daily to earn more Growth Points and win amazing prizes!
➡️ https://www.gate.io/post
🔥 This round features upgraded prizes — with surprise rewards waiting for you!
For more Growth Points tasks, tap the Growth Points icon next to your Gate Post avatar.
Thank you for your support and engagement — we’re here to reward your every effort!
#CommunityGrowthPoints#
Novo Nordisk: 7.2mg semaglutide phase 3 clinical trial met the primary endpoint with a weight loss of 20.7% at 72 weeks.
On January 18, Jins data reported that on January 17 local time, Novo Nordisk announced the main results of the 3b phase clinical trial STEP UP. In the STEP UP obesity trial, subcutaneous injection of 7.2mg semaglutide once a week resulted in a weight loss of 20.7% at 72 weeks, and a weight loss of 18.7% regardless of treatment compliance. The trial met its primary endpoint, with 7.2mg semaglutide showing statistically significant and superior weight loss compared to placebo at 72 weeks.